Moreover, in a recent review by Ma et al., the orthosteric FPR2 agonistic hexapeptide, WKYMVm, has been discussed as a potential therapeutic to treat inflammation, cancer, angiogenesis, tissue repair, neurodegenerative diseases, vaccine development, insulin resistance and osteolytic diseases (83). The gene discussed is FPR2; the disease is neurodegenerative disease.